Krystal Biotech Inc (KRYS)

Current ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Total current assets	US$ in thousands	742,045	713,164	682,772	602,248	587,909	582,128	484,004	355,429	383,779	397,578	428,770	437,998	442,267	345,812	369,927	405,826	275,058	287,652	298,539	188,329
Total current liabilities	US$ in thousands	101,995	89,527	71,851	47,589	33,094	27,583	23,898	35,076	28,847	28,032	34,427	60,437	25,736	35,779	18,119	9,144	15,452	7,198	5,831	4,061
Current ratio		7.28	7.97	9.50	12.66	17.76	21.10	20.25	10.13	13.30	14.18	12.45	7.25	17.18	9.67	20.42	44.38	17.80	39.96	51.20	46.38

December 31, 2024 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $742,045K ÷ $101,995K
= 7.28

The current ratio of Krystal Biotech Inc has fluctuated over the reported periods. Starting at an exceptionally high level of 46.38 on March 31, 2020, the current ratio remained relatively stable above 10 until March 31, 2023. However, it decreased to 7.25 on March 31, 2022, and further dropped to 7.28 on December 31, 2024. This indicates that as of the most recent reporting period, Krystal Biotech Inc may be facing challenges in meeting its short-term financial obligations with its current assets, as the current ratio is below the generally recommended benchmark of 1.

Overall, a declining trend in the current ratio suggests a potential liquidity issue for the company, as it now has a reduced ability to cover its current liabilities using its current assets. It is important for stakeholders to monitor this ratio closely to assess the company's ability to manage its short-term financial commitments effectively.